WuXi AppTec Files Federal Lawsuit Against U.S. Department of Defense Over Erroneous Inclusion on Chinese Military Companies List
Company

WuXi AppTec Files Federal Lawsuit Against U.S. Department of Defense Over Erroneous Inclusion on Chinese Military Companies List

HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies
CompanyDeals

HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies

CompanyDrug

LongBio Pharma’s Anti-IgE Antibody LP-003 Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Trial

Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline
CompanyDeals

Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline

CompanyDrug

Novartis’ Del-Brax Meets Primary Endpoints in FSHD Biomarker Study – Potential First Disease-Modifying Therapy for Rare Muscular Dystrophy

CompanyDeals

QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug

Novartis Secures Fourth China Approval for Tafinlar-Mekinist Combo in BRAF V600E-Mutated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
CompanyDrug

Novartis Secures Fourth China Approval for Tafinlar-Mekinist Combo in BRAF V600E-Mutated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

CompanyDrug

Yipinhong Pharmacy Receives NMPA Clearance for APH03571 Dual-Mechanism Therapy in FLT3-Mutated Relapsed/Refractory AML

CompanyDrug

CSPC Pharmaceutical’s Phase III Trial of Anbenitamab-Docetaxel Combination Meets Primary Endpoint in First-Line HER2-Positive Advanced Breast Cancer

Others

Harbour BioMed’s IND for HBM7004 Bispecific Antibody Accepted by NMPA for Advanced Solid Tumors Following U.S. Clearance

CompanyDeals

QingSong Health and Basel Medical Forge Three-Year Strategic Alliance to Deploy AI-Driven Healthcare Solutions Across Southeast Asia

CompanyDrug

Imviva Biotech Receives FDA Clearance for Phase 1b Basket Trial of CTA313 Allogeneic CAR-T Therapy in B Cell-Mediated Autoimmune Diseases